Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ENSC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsEnsysce closes $2M dilutive financing with full-ratchet anti-dilution warrants
Filed April 8, 2026 · Period ending April 7, 2026 · ~1 min read
Key Changes
-
high
Company raised $2M gross ($1.9M net) by issuing Series B preferred convertible into 4.4M shares plus warrants for 8.7M more shares at $0.55 exercise price. Warrants include full-ratchet anti-dilution protection that automatically lowers exercise price if company issues shares below $0.55.
Item 1.01 verify on EDGAR → -
high
Preferred stock conversion price already 'reduced significantly' since November 2025 due to anti-dilution adjustments, indicating company has issued shares at lower prices and triggered downward repricing that increases dilution to existing shareholders.
Item 1.01 verify on EDGAR → -
medium
Company agreed to restrictions on issuing new equity or filing registration statements while investor holds at least $100K of preferred stock. Also prohibited from variable-rate convertible transactions, limiting future financing flexibility.
Item 1.01 verify on EDGAR → -
medium
Series B preferred stated value increased from $1,100 to $1,200 per share as part of deal terms, affecting liquidation preference and potentially other rights relative to common shareholders.
Item 1.01 verify on EDGAR → -
medium
Securities sold in unregistered private placement to accredited institutional investor under Regulation D exemption. Warrants split between 18-month and 5-year expiration periods.
Item 3.02 verify on EDGAR →
Summary
Ensysce Biosciences closed a $2 million private placement on April 6, 2026, issuing Series B preferred stock and warrants to an institutional investor. The financing is highly dilutive: the preferred converts into 4.4 million common shares at $0.55, and warrants cover another 8.7 million shares at the same price.
Critically, both securities include full-ratchet anti-dilution provisions that automatically lower conversion and exercise prices if the company issues shares below $0.55 in the future. The filing reveals the conversion price has already been 'reduced significantly' since the initial November 2025 issuance, meaning prior stock sales at lower prices have triggered repricing and amplified dilution.
Retail holders should care because this structure creates a downward spiral risk: any future capital raise at depressed prices will further reduce the conversion price, issuing more shares to the preferred holder and diluting common shareholders even more. The company also accepted restrictions on future equity issuances and variable-rate transactions while the investor holds at least $100,000 of preferred stock, constraining financing options. Watch for the company's next capital raise—if it occurs below $0.55 per share, expect immediate repricing and accelerated dilution. The net proceeds of $1.9 million will fund TAAP and MPAR drug development programs and working capital.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Ensysce closed $2M private placement of Series B preferred stock and warrants with institutional investor on April 6, 2026.
Added in current filing · verify on EDGAR →
On April 6, 2026 (the “Closing Date”), pursuant to the Purchase Agreement and Subsequent Purchase Notice, the Company privately issued and sold (i) 2,000 shares (the “Shares”) of Series B preferred stock of the Company, par value $0.0001 per share (the “Preferred Stock”), (ii) up to 4,363,636 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”) to be issued upon conversion of the Preferred Stock, and (iii) warrants to purchase up to 8,727,273 shares of Common Stock (the “Warrants”), all subject to adjustment, for gross proceeds of $2 million before the deduction of fees and offering expenses (the “Offering”).
The company completed a $2 million private placement by issuing 2,000 shares of Series B preferred stock convertible into up to 4.4 million common shares, plus warrants to purchase up to 8.7 million additional common shares. The net proceeds of approximately $1.9 million will be used for continued development of TAAP and MPAR programs and working capital.
Added in current filing · verify on EDGAR →
The Warrants have an exercise price of $0.55, subject to adjustment (the “Exercise Price”), and are exercisable at any time after the date of issuance, with Warrants for 4,363,637 shares exercisable for 18 months after the date of issuance and Warrants for 4,363,636 shares exercisable for five years after the date of issuance. ... Pursuant to the terms of the Warrants, our issuances of shares of Common Stock at prices per share below the Exercise Price (including issuances pursuant to the Purchase Agreement or Subsequent Purchase Notice) will result in an adjusted exercise price of the Warrants lower than the Exercise Price.
The warrants have a $0.55 exercise price with full ratchet anti-dilution protection, meaning any future stock issuances below $0.55 will automatically reduce the warrant exercise price to that lower price. Half the warrants expire in 18 months, half in five years. This creates significant potential dilution risk for existing shareholders if the company issues shares at lower prices.
Added in current filing · verify on EDGAR →
In the Offering, the conversion price per share of Preferred Stock is also $0.55 (the “Conversion Price”), subject to adjustment. Following the November 2025 sale, pursuant to the adjustment provisions in the Certificate of Designation, the Conversion Price has been reduced significantly as of the Closing Date.
The Series B preferred stock converts to common stock at $0.55 per share, but the conversion price has already been "reduced significantly" since the November 2025 issuance due to anti-dilution adjustments. This indicates the company has issued shares at lower prices in the interim, triggering downward repricing and increasing dilution to existing shareholders.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Item 3.02 — Unregistered Sales of Equity Securities filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Based in part upon the representations of the Purchaser in the Purchase Agreement, the offer and sale of securities in the Offering are exempt from registration under Section 4(a) (2) of the Securities Act, Rule 506 of Regulation D promulgated under the Securities Act, and corresponding provisions of state securities or “blue sky” laws.
The company sold securities in a private placement without SEC registration, relying on exemptions for sales to accredited investors. The purchaser represented it is an accredited investor or qualified institutional buyer acquiring securities for investment purposes only, not for resale. This is a common capital-raising method for smaller companies but dilutes existing shareholders.
Added in current filing · verify on EDGAR →
the Purchaser represented, among other things, that it is and, on each date on which it converts any shares of Preferred Stock or exercises any Warrants, will be either (i) an accredited investor, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act
The offering included Preferred Stock convertible to Common Stock and Warrants exercisable for Common Stock. The specific terms, pricing, and potential dilution impact are referenced in Item 1.01 (not provided in this excerpt). Investors should review the full filing to understand the conversion terms and warrant exercise prices.
Event · Item 8.01 — Other Events
Company announced a securities offering via press release on April 7, 2026.
Added in current filing · verify on EDGAR →
On April 7, 2026, the Company issued a press release announcing the Offering.
Ensysce Biosciences announced a securities offering through a press release.1). This is a capital-raising event that could dilute existing shareholders or strengthen the balance sheet depending on terms.
Event · Item 9.01 — Financial Statements and Exhibits
Ensysce disclosed a securities offering completed April 6, 2026, issuing warrants and Series B Preferred Stock under a November 2025 purchase agreement.
Added in current filing · verify on EDGAR →
Forms of Warrants issued in the Offering that occurred on April 6, 2026
The company completed a securities offering on April 6, 2026, issuing warrants. This offering appears to be a subsequent closing under a Securities Purchase Agreement originally dated November 13, 2025, as evidenced by a Subsequent Purchase Notice dated April 2, 2026. The offering likely raised capital for the company's operations.
Added in current filing · verify on EDGAR →
Certificate of Amendment to Certificate of Designation of Series B Preferred Stock
The company filed an amendment to the Certificate of Designation for its Series B Preferred Stock. This follows prior corrections filed in November 2025 and March 2026, suggesting ongoing modifications to the terms of this preferred stock class. The specific changes are not detailed in this 8-K but could affect preferred shareholder rights or conversion terms.
Added in current filing · verify on EDGAR →
Subsequent Purchase Notice, dated as of April 2, 2026, between the Company and the purchaser thereto
A Subsequent Purchase Notice dated April 2, 2026 was executed under the November 2025 Securities Purchase Agreement. This notice likely triggered the April 6 offering, allowing the purchaser to acquire additional securities under pre-negotiated terms. Such arrangements can result in dilution to existing shareholders.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify